FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	Tok	2. Issuer Name and Ticker or Trading Symbol Tokai Pharmaceuticals Inc [TKAI]										Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner								
(Last)	(Fir	st) (N	/liddle))	3. Date of Earliest Transaction (Month/Day/Year) 09/08/2015										X	X Officer (give title below)			Other (specify below)	
C/O TOK	AI PHARM												Chief Financial Officer							
255 STA	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street)												X Form filed by One Reporting Person								
BOSTON	I M	Α 0	2109													Form filed by More than One Reporti Person				
(City)	(Sta	ate) (Z	⊻ ip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execution Date,			3. 4. Securities Acquired Disposed Of (D) (Instr. 8)							Securities Beneficially Owned		nership : Direct - ect (I) . 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	Code V		(A) or (D)		Price		Reported Transaction(s) (Instr. 3 and 4)				(
Common)15				S ⁽¹⁾		4,668	D \$		\$13.1	3(2)	40,953(3)			D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4) Amou or Numb		f g nstr. nount	nt		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)		Beneficial Ownership	
					Code	V (A) (D)		Date Exercisable		Expiration Date	Title	of								

Explanation of Responses:

- 1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.11 to \$13.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.

Remarks:

/s/ Cindy Driscoll, Attorneyin-Fact 09/08/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.